PURPOSE: In a continuous effort to seek for anticancer treatments with minimal side effects, we aim at proving the feasibility of the Intraoperative Avidination for Radionuclide Therapy, a new procedure for partial breast irradiation. EXPERIMENTAL DESIGN: To assess doses of 90Y-DOTA-biotin to target (i.e., breast tumor bed) and nontarget organs, we did simulation studies with 111In-DOTA-biotin in 10 candidates for conservative breast surgery. Immediately after quadrantectomy, patients were injected with 100-mg avidin in the tumor bed. On the following day, patients were given 111In-DOTA-biotin (approximately 111 MBq) i.v. after appropriate chase of biotinylated albumin (20 mg) to remove circulating avidin. Biokinetic studies were done by measuring radioactivity in scheduled blood samples, 48-h urine collection, and through scintigraphic images. The medical internal radiation dose formalism (OLINDA code) enabled dosimetry assessment in target and nontarget organs. RESULTS: Images showed early and long-lasting radioactive biotin uptake in the operated breast. Rapid blood clearance (<1% at 12 h) and urine excretion (>75% at 24 h) were observed. Absorbed doses, expressed as mean+/-SD in Gy/GBq, were as low as 0.15+/-0.05 in lungs, 0.10+/-0.02 in heart, 0.06+/-0.02 in red marrow, 1.30+/-0.50 in kidneys, 1.50+/-0.30 in urinary bladder, and 0.06+/-0.02 in total body, whereas in the targeted area, they increased to 5.5+/-1.1 Gy/GBq (50% ISOROI) and 4.8+/-1.0 Gy/GBq (30% ISOROI). CONCLUSION: Our preliminary results suggest that Intraoperative Avidination for Radionuclide Therapy is a simple and feasible procedure that may improve breast cancer patients' postsurgical management by shortening radiotherapy duration.
PURPOSE: In a continuous effort to seek for anticancer treatments with minimal side effects, we aim at proving the feasibility of the Intraoperative Avidination for Radionuclide Therapy, a new procedure for partial breast irradiation. EXPERIMENTAL DESIGN: To assess doses of 90Y-DOTA-biotin to target (i.e., breast tumor bed) and nontarget organs, we did simulation studies with 111In-DOTA-biotin in 10 candidates for conservative breast surgery. Immediately after quadrantectomy, patients were injected with 100-mg avidin in the tumor bed. On the following day, patients were given 111In-DOTA-biotin (approximately 111 MBq) i.v. after appropriate chase of biotinylated albumin (20 mg) to remove circulating avidin. Biokinetic studies were done by measuring radioactivity in scheduled blood samples, 48-h urine collection, and through scintigraphic images. The medical internal radiation dose formalism (OLINDA code) enabled dosimetry assessment in target and nontarget organs. RESULTS: Images showed early and long-lasting radioactive biotin uptake in the operated breast. Rapid blood clearance (<1% at 12 h) and urine excretion (>75% at 24 h) were observed. Absorbed doses, expressed as mean+/-SD in Gy/GBq, were as low as 0.15+/-0.05 in lungs, 0.10+/-0.02 in heart, 0.06+/-0.02 in red marrow, 1.30+/-0.50 in kidneys, 1.50+/-0.30 in urinary bladder, and 0.06+/-0.02 in total body, whereas in the targeted area, they increased to 5.5+/-1.1 Gy/GBq (50% ISOROI) and 4.8+/-1.0 Gy/GBq (30% ISOROI). CONCLUSION: Our preliminary results suggest that Intraoperative Avidination for Radionuclide Therapy is a simple and feasible procedure that may improve breast cancerpatients' postsurgical management by shortening radiotherapy duration.
Authors: Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-03 Impact factor: 9.236
Authors: Rita De Santis; Claudio Albertoni; Antonio Rosi; Barbara Leoni; Fiorella Petronzelli; Valeria D'Alessio; Eleonora Nucera; Giovanni Salvatori; Giovanni Paganelli; Antonio Verdoliva; Paolo Carminati; Carlo Antonio Nuzzolo Journal: J Biomed Biotechnol Date: 2010-01-10
Authors: Giovanni Paganelli; Concetta De Cicco; Mahila E Ferrari; Giuseppe Carbone; Gianmatteo Pagani; Maria Cristina Leonardi; Marta Cremonesi; Annamaria Ferrari; Monica Pacifici; Amalia Di Dia; Rita De Santis; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Stefano Zurrida; Umberto Veronesi Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-04 Impact factor: 9.236
Authors: G Paganelli; C De Cicco; M E Ferrari; G McVie; G Pagani; M C Leonardi; M Cremonesi; A Ferrari; M Pacifici; A Di Dia; F Botta; R De Santis; V Galimberti; A Luini; R Orecchia; U Veronesi Journal: Ecancermedicalscience Date: 2010-11-01
Authors: Ferdinando Maria Milazzo; Anna Maria Anastasi; Caterina Chiapparino; Antonio Rosi; Barbara Leoni; Loredana Vesci; Fiorella Petronzelli; Rita De Santis Journal: Oncotarget Date: 2017-04-04